Abstract

BackgroundInflammation may trigger skeletal muscle atrophy induced by cancer cachexia. As a pro-inflammatory factor, interleukin-6 may cause skeletal muscle atrophy, but the underlying molecular mechanisms have not been explored.MethodsIn this experimental study, we used adult male ICR mice, weighing 25 ± 2 g, and the continuous infusion of interleukin-6 into the tibialis anterior muscle to construct a skeletal muscle atrophy model (experimental group). A control group received a saline infusion. RNA-sequencing was used to analyze the differentially expressed genes in tissue samples after one and three days. Gene Ontology and the Kyoto Encyclopedia of Genes and Genomes analysis were applied to define the function of these genes, and protein-protein interaction analysis was performed to identify potential transcription factors. Fluorescence microscopy was used to determine the muscle fiber cross-sectional area after 14 days.ResultsContinuous infusion of interleukin-6 for 14 days caused significant muscle atrophy. RNA-sequencing found 359 differentially expressed genes in the 1- and 3-day tissue samples and 1748 differentially expressed genes only in the 3-day samples. Functional analysis showed that the differentially expressed genes found in both the 1- and 3-day samples were associated with immune receptor activation, whereas the differentially expressed genes found only in the 3-day sample were associated with reduced energy metabolism. The expression of multiple genes in the oxidative phosphorylation and tricarboxylic acid cycle pathways was down-regulated. Furthermore, differentially expressed transcription factors were identified, and their interaction with interleukin-6 and the differentially expressed genes was predicted, which indicated that STAT3, NF-κB, TP53 and MyoG may play an important role in the process of interleukin-6-induced muscle atrophy.ConclusionsThis study found that interleukin-6 caused skeletal muscle atrophy through immune receptor activation and a reduction of the energy metabolism. Several transcription factors downstream of IL-6 have the potential to become new regulators of skeletal muscle atrophy. This study not only enriches the molecular regulation mechanism of muscle atrophy, but also provides a potential target for targeted therapy of muscle atrophy.

Highlights

  • Inflammation may trigger skeletal muscle atrophy induced by cancer cachexia

  • The number of up-regulated genes was larger than that of down-regulated genes, the Pvalue for oxidation-reduction processes was much lower than that of the immune system process (6.21E-24 vs. 2.49E-18; Figure 4B). These results suggested that the main function of the differentially expressed genes (DEGs) was in the pathways related to reducing the energy metabolism, the immune system continued to be activated after three days

  • A study conducted in patients with non-small cell lung cancer (NSCLC) and muscle atrophy pointed out that the overexpression of IL-6 and IL-8 can be potentially used as biomarkers of a poor prognosis in patients with NSCLC [35]

Read more

Summary

Introduction

Inflammation may trigger skeletal muscle atrophy induced by cancer cachexia. As a pro-inflammatory factor, interleukin-6 may cause skeletal muscle atrophy, but the underlying molecular mechanisms have not been explored. The balance can be disturbed by various factors, such as cancer cachexia, mechanical damage, denervation, bed rest, and diabetes that trigger skeletal muscle atrophy [3]. Cancer cachexia is a metabolic disease characterized by systemic inflammation and skeletal muscle atrophy, which seriously affects patients’ quality of life and is related to their survival rate [4]. Lung cancer patients with cachexia who develop skeletal muscle atrophy have a shorter overall survival rate and less favorable response to PD-1 antibody treatment [5]. Alleviating skeletal muscle atrophy may slow down the progression of cancer cachexia. There are no drugs that effectively treat skeletal muscle atrophy to date, and in-depth studies of the molecular mechanisms underlying skeletal muscle atrophy are warranted to facilitate the development of specific therapeutic approaches

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call